Home

The Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective is a key educational event, jointly hosted by the Cancer Genomics Program (CGP) and the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. The objective of this Symposium is to provide a clinical and translational perspective on cancer genomics and tumor immunotherapy by highlighting emerging therapies and technologies as they apply to precision cancer medicine at the point of care. Participants will learn about new research on mechanisms of resistance and response, emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomic applications in the clinic.

This one-day symposium will be a hybrid event this year, held both in-person and virtually.

 

Confirmed speakers include:

Paul Mischel, MD, Stanford University

Aadel Chaudhuri, MD, PhD, Mayo Clinic

Erica Tsang, MD, Princess Margaret Cancer Centre

Raymond Kim, MD, PhD, Princess Margaret Cancer Centre

Intan Schrader, MD, PhD, BC Cancer

Wolf H. Fridman, MD, University of Paris

Anastasia Tikhonova, PhD, Princess Margaret Cancer Centre

Grégoire Marret, MD, PhD, Princess Margaret Cancer Centre

 

Target Audience for the 2024 Cancer Genomics and Tumor Immunotherapy Symposium:

  • Oncologists: Medical, Radiation, Surgical
  • Pathologists
  • Clinical Geneticists
  • Genetic Counselors
  • Laboratory Directors
  • Laboratory Technicians
  • Oncology Nurses
  • Bioinformaticians
  • Basic and Translational Scientists
  • Basic, Translational and Clinical Trainees
  • Pharmaceutical Representatives

 

Topics to be discussed in a presentation or panel include:

  • Extrachromosomal DNA and its Impact in Cancer 
  • Next Generation ctDNA Technologies
  • Drug Tolerant Persister Cells and Treatment Resistance in Cancer
  • Tertiary Lymphoid Structures in Cancer
  • Tumor Microenvironment and Leukemia
  • Spatial Transcriptomic Analysis of Head and Neck Cancer
  • Multi-omic Analysis: Linking Data Science to Molecular Biology
  • Updates on Cell Therapies
  • Debate: Universal germline sequencing should be offered to all adult patients with a new cancer diagnosis